Sygnia founder Magda Wierzycka lifts lid on how her company bought into Oxford’s Covid-19 vaccine
Loading player...
UPDATE: The headline has been changed to make it clear that neither Sygnia nor any other investors funding the development of the vaccine will profit from it during the pandemic. The return on investment will only come in future years - IF the vaccine works. We sincerely apologise for the previous headline creating the wrong impression. - Editor
Sygnia founder and CEO Magda Wierzycka, is among a handful of SA business leaders who truly sees the world as her oyster. Well known for her forward thinking, she in 2015 bought shares in OSI, a company that transforms patents from Oxford University into viable businesses for 25% ownership. Within the OSI stable is Vaccitech, a company that has been developing a vaccine for MERS virus and has put them ahead of the Covid-19 vaccine race. Sygnia, the single biggest shareholder of OSI, is well placed to reap the rewards once the vaccine is made commercial. - Vanessa Marks
Sygnia founder and CEO Magda Wierzycka, is among a handful of SA business leaders who truly sees the world as her oyster. Well known for her forward thinking, she in 2015 bought shares in OSI, a company that transforms patents from Oxford University into viable businesses for 25% ownership. Within the OSI stable is Vaccitech, a company that has been developing a vaccine for MERS virus and has put them ahead of the Covid-19 vaccine race. Sygnia, the single biggest shareholder of OSI, is well placed to reap the rewards once the vaccine is made commercial. - Vanessa Marks
